Center for Molecular Medicine, Department of Vascular Matrix Biology, Excellence Cluster Cardio-Pulmonary System, Frankfurt University Hospital, 60590 Frankfurt, Germany.
J Biol Chem. 2013 Jan 11;288(2):947-55. doi: 10.1074/jbc.M112.399618. Epub 2012 Nov 30.
Many snake venoms are known for their antithrombotic activity. They contain components that specifically target different platelet-activating receptors such as the collagen-binding integrin α2β1 and the von Willebrand factor receptor GPIb. In a search for an α2β1 integrin-blocking component from the venom of the habu snake (Trimeresurus flavoviridis), we employed two independent purification protocols. First, we used the integrin α2A domain, a major collagen-binding domain, as bait for affinity purification of an α2β1 integrin-binding toxin from the crude venom. Second, in parallel, we used classical protein separation protocols and tested for α2β1 integrin-inhibiting capabilities by ELISA. Using both approaches, we identified flavocetin-A as an inhibitor of α2β1 integrin. Hitherto, flavocetin-A has been reported as a GPIb inhibitor. However, flavocetin-A inhibited collagen-induced platelet aggregation even after GPIb was blocked with other inhibitors. Moreover, flavocetin-A antagonized α2β1 integrin-mediated adhesion and migration of HT1080 human fibrosarcoma cells, which lack any GPIb, on collagen. Protein chemical analyses proved that flavocetin-A binds to α2β1 integrin and its α2A domain with high affinity and in a cooperative manner, which most likely is due to its quaternary structure. Kinetic measurements confirmed the formation of a strong complex between integrin and flavocetin-A, which dissociates very slowly. This study proves that flavocetin-A, which has long been known as a GPIb inhibitor, efficiently targets α2β1 integrin and thus blocks collagen-induced platelet activation. Moreover, our findings suggest that the separation of GPIb- and α2β1 integrin-blocking members within the C-type lectin-related protein family is less strict than previously assumed.
许多蛇毒以其抗血栓活性而闻名。它们含有专门针对不同血小板激活受体的成分,如胶原蛋白结合整合素α2β1 和 von Willebrand 因子受体 GPIb。在寻找来自眼镜蛇(Trimeresurus flavoviridis)毒液的α2β1 整合素阻断成分时,我们采用了两种独立的纯化方案。首先,我们使用整合素α2A 结构域,这是一个主要的胶原蛋白结合结构域,作为诱饵,从粗毒液中亲和纯化α2β1 整合素结合毒素。其次,我们同时使用经典的蛋白质分离方案,并通过 ELISA 测试其对α2β1 整合素的抑制能力。通过这两种方法,我们鉴定出 flavocetin-A 是α2β1 整合素的抑制剂。迄今为止,flavocetin-A 已被报道为 GPIb 抑制剂。然而,即使在用其他抑制剂阻断 GPIb 后,flavocetin-A 仍能抑制胶原诱导的血小板聚集。此外,flavocetin-A 拮抗 HT1080 人纤维肉瘤细胞上α2β1 整合素介导的黏附和迁移,而这些细胞缺乏任何 GPIb,但在胶原上。蛋白质化学分析证明 flavocetin-A 以高亲和力和协同方式与α2β1 整合素及其α2A 结构域结合,这很可能是由于其四级结构。动力学测量证实了整合素和 flavocetin-A 之间形成了一个强复合物,其解离非常缓慢。这项研究证明,flavocetin-A 长期以来一直被认为是 GPIb 抑制剂,它能有效地靶向α2β1 整合素,从而阻断胶原诱导的血小板激活。此外,我们的发现表明,C 型凝集素相关蛋白家族中 GPIb 和α2β1 整合素阻断成员的分离不如以前假设的那么严格。